References
- Uberall MA, Mueller-Schwefe GH, Terhaag B. Efficacy and safety of flupirtine modified release for the management of moderate to severe chronic low back pain: results of SUPREME, a prospective randomized, double-blind, placebo- and active-controlled parallel-group phase IV study. Curr Med Res Opin 2012;28:1617-34
- Michel MC, Radziszewski P, Falconer C, et al. Unexpected frequent hepatotoxicity of a prescription drug, flupirtine, marketed for about 30 years. Br J Clin Pharmacol 2012;73:821-5
- Li C, Ni J, Wang Z, et al. Analgesic efficacy and tolerability of flupirtine vs. tramadol in patients with subacute low back pain: a double-blind multicentre trial*. Curr Med Res Opin 2008;24:3523-30
- European Medicines Agency. Notification of a referral under Article 107i of Directive 2001/83/EC. London, UK: EMA; February 28, 2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Flupirtine-containing_medicines/Procedure_started/WC500139756.pdf [Last accessed 28 September 2017]
- European Medicines Agency: EMA/404308/2013. Assessment report for flupirtine containing medicinal products. London, UK: EMA; September 24, 2013; Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Flupirtine-containing_medicines/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee/WC500146103.pdf [Last accessed 24 September 2017]
- Summary of Product Characteristics: Flupirtine. London, UK; 2015. Available at: http://mri.cts-mrp.eu/download/DE_H_3430_001_FinalSPC_2of2.pdf [Last accessed 28 September 2017]
- European Medicines Agency. Withdrawal of pain medicine flupirtine endorsed. London, UK: EMA; March 23, 2018. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Flupirtine-31/Position_provided_by_CMDh/WC500248611.pdf [Last accessed 18 June 2018]
- Chen M, Suzuki A, Borlak J, et al. Drug-induced liver injury: Interactions between drug properties and host factors. J Hepatol 2015;63:503-14
- Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol 2014;109:950-66; quiz 67
- Curtis LH, Ostbye T, Sendersky V, et al. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med 2003;114:135-41
- Piening S, Haaijer-Ruskamp FM, de Vries JT, et al. Impact of safety-related regulatory action on clinical practice: a systematic review. Drug Saf 2012;35:373-85
- Piening S, Reber KC, Wieringa JE, et al. Impact of safety-related regulatory action on drug use in ambulatory care in the Netherlands. Clin Pharmacol Ther 2012;91:838-45
- Kruik-Kolloffel WJ, van der Palen J, Kruik HJ, et al. Prescription behavior for gastroprotective drugs in new users as a result of communications regarding clopidogrel – proton pump inhibitor interaction. Pharmacol Res Perspect 2016;4:e00242
- Laramee P, Kusel J, Leonard S, et al. The economic burden of alcohol dependence in Europe. Alcohol Alcohol 2013;48:259-69
- Gordon DB, Pellino TA, Higgins GA, et al. Nurses’ opinions on appropriate administration of PRN range opioid analgesic orders for acute pain. Pain Manag Nurs 2008;9:131-40
- Schug SA, Palmer GM, Scott DA, et al. Acute pain management: scientific evidence, fourth edition, 2015. Med J Aust 2016;204:315-17
- Lewis NL, Williams JE. Acute pain management in patients receiving opioids for chronic and cancer pain. Contin Educ Anaesth Crit Care Pain 2005;5:127-9